CalciMedica Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
CALC$1.37-9.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Equity | |
| Balance—December 31, 2023 | 5,754,505 | $1 | $154,218 | $(146,064) | $2 | $8,157 |
| Stock-based compensation expense | — | — | 414 | — | — | 414 |
| Issuance of common shares from private placement (net of issuance costs) | 4,985,610 | 2 | 7,903 | — | — | 7,905 |
| Issuance of warrants in connection with the private placement | — | — | 660 | — | — | 660 |
| Unrealized loss on investments | — | — | — | — | (19) | (19) |
| Net income | — | — | — | 130 | — | 130 |
| Balance—March 31, 2024 | 10,740,115 | $3 | $163,195 | $(145,934) | $(17) | $17,247 |
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
| Convertible Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · TotalStockholders’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Shares · Amount · Capital · Deficit · Equity/(Deficit) | ||||||||||
| Balance—December 31, 2022 | 84,820,880 | 62,071 | 84,165 | 1 | 40,402 | (111,707) | (71,304) | |||
| Stock-based compensation expense | — | — | — | — | 11,126 | — | 11,126 | |||
| Conversion of preferred stock to common stock as a result of Merger | (84,820,880) | (62,071) | 2,442,852 | — | 62,071 | — | 62,071 | |||
| Issuance of common stock to Graybug stockholders as a result of Merger and reset to par of $0.0001 | — | — | 1,571,433 | 29,218 | — | 29,218 | ||||
| Issuance of common shares from private placement (net of issuance costs) | — | — | 596,363 | — | 10,340 | — | 10,340 | |||
| Conversion of promissory notes into common stock | — | — | 590,031 | — | 3,245 | — | 3,245 | |||
| Conversion of Series C-2 warrants into common stock | — | — | 80,254 | — | 442 | — | 442 | |||
| Conversion of promissory note warrants into common stock | — | — | 152,875 | — | 841 | — | 841 | |||
| Merger transaction costs | — | — | — | — | (4,591) | — | (4,591) | |||
| Restricted stock units net settlement | — | — | — | — | (297) | — | (297) | |||
| Reclassification of warrant liability to equity | — | — | — | — | 216 | — | 216 | |||
| Net loss | — | — | — | — | — | (19,288) | (19,288) | |||
| Balance—March 31, 2023 | — | — | 5,517,973 | $1 | $153,013 | $(130,995) | $22,019 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.